Back to discover

Protein / target

Toll-like receptor 4

Encoded byTLR4O00206Homo sapiensSwiss-Prot
Clinical-stage
Therapeutic maturity
3
Clinical candidates
Small-molecule tractable
Druggability
Advanced Clinical
22
Research papers

Protein at a glance

Biological role

Lipopolysaccharide immune receptor

Strongest disease association

Major depressive disorder

Via encoding gene TLR4 · Genetic evidence · score 0.79

Therapeutic position

Clinically advancing target

Small molecules

Research activity

Emerging research

22 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways.

View complete UniProt function annotation

Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways (PubMed:10835634, PubMed:15809303, PubMed:16622205, PubMed:17292937, PubMed:17478729, PubMed:20037584, PubMed:20711192, PubMed:23880187, PubMed:27022195, PubMed:29038465, PubMed:17803912, PubMed:15852007). At the plasma membrane, cooperates with LY96 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:27022195). Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+) (PubMed:20711192). Mechanistically, acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:10835634, PubMed:21393102, PubMed:27022195, PubMed:36945827, PubMed:9237759). Alternatively, CD14-mediated TLR4 internalization via endocytosis is associated with the initiation of a MYD88-independent signaling via the TICAM1-TBK1-IRF3 axis leading to type I interferon production (PubMed:14517278). In addition to the secretion of proinflammatory cytokines, initiates the activation of NLRP3 inflammasome and formation of a positive feedback loop between autophagy and NF-kappa-B signaling cascade (PubMed:32894580). In complex with TLR6, promotes inflammation in monocytes/macrophages by associating with TLR6 and the receptor CD86 (PubMed:23880187). Upon ligand binding, such as oxLDL or amyloid-beta 42, the TLR4:TLR6 complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway (PubMed:23880187). In myeloid dendritic cells, vesicular stomatitis virus glycoprotein G but not LPS promotes the activation of IRF7, leading to type I IFN production in a CD14-dependent manner (PubMed:15265881, PubMed:23880187). Required for the migration-promoting effects of ZG16B/PAUF on pancreatic cancer cells

Subcellular location

Cell membraneEarly endosomeCell projection, ruffle
Domains and Gene Ontology detail (78)

Domains & features

LRRCTTIR

Gene Ontology

  • Ccell surface
  • Ccytoplasm
  • Cearly endosome
  • Cendosome membrane
  • Cexternal side of plasma membrane
  • Clipopolysaccharide receptor complex
  • Cperinuclear region of cytoplasm
  • Cphagocytic cup
  • Cplasma membrane
  • Creceptor complex
  • Cruffle
  • Famyloid-beta binding

839 aa · 96 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt · GOImmune signallingUniProt · GOTranscriptional regulationGO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·Transmembrane receptor that functions as a pattern recognition receptor recognizing path…
  • ·cellular response to oxidised low-density lipoprotein particle stimulus

Immune signalling

  • ·Transmembrane receptor that functions as a pattern recognition receptor recognizing path…
  • ·immune response
  • ·inflammatory response
  • ·innate immune response

Transcriptional regulation

  • ·positive regulation of gene expression
  • ·positive regulation of transcription by RNA polymerase II

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TLR4

Gene-level evidence surfaced through the gene TLR4 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Major depressive disorder
0.81Well supported

Genetic evidence dominant · Open Targets 0.50

Diabetes Mellitus, Type 2
0.70Moderately supported

Genetic evidence dominant · Open Targets 0.41

Colitis, Ulcerative
0.63Moderately supported

Genetic evidence dominant · Open Targets 0.38

Cholangitis, Sclerosing
0.62Moderately supported

Genetic evidence dominant · Open Targets 0.35

Psoriasis
0.61Moderately supported

Genetic evidence dominant · Open Targets 0.36

View evidence synthesis (5)
Major depressive disorderWell supported
0.81
agreement 0.670.95
Genetic86%Literature14%

Open Targets aggregate 0.50 · 2 independent evidence families

Diabetes Mellitus, Type 2Moderately supported
0.70
agreement 0.590.80
Genetic73%Literature17%Clinical11%

Open Targets aggregate 0.41 · 3 independent evidence families

Colitis, UlcerativeModerately supported
0.63
agreement 0.500.75
Genetic92%Literature6%RNA expression2%

Open Targets aggregate 0.38 · 3 independent evidence families

Cholangitis, SclerosingModerately supported
0.62
agreement 0.500.74
Genetic79%Animal model19%Literature2%

Open Targets aggregate 0.35 · 3 independent evidence families

PsoriasisModerately supported
0.61
agreement 0.470.75
Genetic84%Literature16%

Open Targets aggregate 0.36 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Major depressive disorder0.50
Diabetes Mellitus, Type 20.41
Dengue0.39
Colitis, Ulcerative0.38
Immunologic Deficiency Syndromes0.37
Psoriasis0.36
Cholangitis, Sclerosing0.35
Crohn's Disease0.35
Spondylitis, Ankylosing0.35

Drug development

3 compounds recorded · 3 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (3)
RESATORVIDPhase 3
ERITORAN TETRASODIUMPhase 3
ERITORANPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Advanced Clinical and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (10)
SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

adverse drug eventsClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

22 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Shi H · The Journal of clinical investigation · 2006

Andersson U · Annual review of immunology · 2011

Ciesielska A · Cellular and molecular life sciences : CMLS · 2021

Ohashi K · Journal of immunology (Baltimore, Md. : 1950) · 2000

Recent

IRF3 function and immunological gaps in sepsis.

Basak B · Frontiers in immunology · 2024

TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling.

Ciesielska A · Cellular and molecular life sciences : CMLS · 2021

Europe PMC papers linked directly to this protein.